Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q3 2025 earnings summary

Executive summary

• Achieved significant organizational restructuring, including sale of three general hospitals, contract rescissions, and a strategic focus on core oncology services, supported by a capital increase of approximately R$1.4 billion.

• Largest private oncology provider in Brazil, operating 144 units in 47 cities, with ~670,000 treatments in LTM 3Q25 and over 2,240 oncology specialists.

• Significant non-recurring accounting charges (~R$1.8 billion) and asset write-downs impacted reported results, requiring adjusted figures for recurring performance analysis.

• Attracted over 100 new doctors since the start of the year, reinforcing appeal in the oncology sector.

Financial highlights

• Adjusted EBITDA reached R$241.4 million in 3Q25, up 30.4% sequentially, with a margin of 17.1%, and cash flow from operations was R$246.4 million.

• Gross revenue in 3Q25 was R$1,579.4 million, down 9.5% YoY; net revenue was R$1,413 million, down 13.6% YoY, mainly due to discontinuation of services to Unimed FERJ.

• Net loss for Q3 2025 was R$1,880.70 million, driven by significant non-cash provisions and asset write-downs.

• Organic free cash flow generation was R$62.4 million in the quarter.

• Cash profit was R$456 million, and annualized gross profit reached R$1.8 billion with a 30.7% margin.

Outlook and guidance

• Management expects continued operational recovery, margin expansion, and improved cash flow, with Q4 2025 revenue projected at R$1,470 million and EBITDA ex-PILP at R$235 million.

• Guidance for net revenue growth in the low double digits (10-12%) for the next periods, leveraging existing capacity and partnerships.

• CapEx is projected at R$80 million annually for 2026 and 2027, remaining below historical levels.